Children born profoundly deaf because of mutations in the OTOF gene are hearing speech, music, and everyday sounds after a single gene therapy infusion, and the gains are holding steady for up to 2.5 years. A multicentre trial of 42 participants, ranging from infants to adults and spanning eight clinical centres, has produced the longest follow-up data yet for this approach. On April 23, 2026, the U.S. Food and Drug Administration approved OTARMENI (lunsotogene parvec-cwha), making it the first gene therapy ever cleared for genetic hearing loss. The question now is whether these results can reach the families who need them before a narrow developmental window closes.
Why restored hearing in OTOF-related deafness demands urgency
Autosomal recessive deafness 9, caused by biallelic OTOF mutations, accounts for a small but well-defined share of congenital hearing loss. The protein otoferlin is essential for transmitting sound signals from inner hair cells to the auditory nerve. Without it, children are born profoundly deaf, and cochlear implants have been the only option. Gene therapy changes the calculus by delivering a functional copy of the human OTOF gene directly into the cochlea using an adeno-associated virus (AAV1) vector, a method confirmed across multiple centres.
The urgency is biological. The auditory cortex develops most rapidly in the first two years of life, when incoming sound shapes the neural circuits that support speech and language. Children treated before age two may gain not just louder sound perception but the wiring needed for complex grammar, vocabulary, and social communication. Age-stratified data from early cohorts suggest that younger children show steeper improvements in sentence recognition and conversational understanding than those treated later, even when pure-tone thresholds improve by similar amounts.
A reasonable hypothesis, drawn from these emerging patterns, is that intervention before prolonged auditory deprivation will produce measurably better language outcomes at school age than treatment started in preschool or later. The current trials do not yet have five-year language data to confirm or refute that hypothesis, but the trend lines already point in that direction. A separate study that included older participants found that the duration of deafness before treatment strongly influenced speech outcomes, reinforcing the idea that timing is not incidental but central to the therapy’s real-world value.
Trial data from 42 participants across 2.5 years
The primary evidence for OTARMENI comes from a single-arm trial that enrolled 42 participants and followed them for up to 2.5 years. The study, reported in a Nature analysis, used an AAV1 vector carrying the human OTOF gene, delivered via intracochlear infusion under general anaesthesia. Investigators measured pure-tone averages, auditory brainstem response (ABR), and speech perception trajectories at regular intervals after dosing.
Across the cohort, most treated ears moved from the range of profound deafness into the mild-to-moderate hearing-loss range on pure-tone testing. ABR recordings, which had been absent or severely abnormal before therapy, showed clear waveforms consistent with restored synaptic transmission between inner hair cells and the auditory nerve. Importantly, these gains did not fade: hearing thresholds and speech scores remained broadly stable through the 2.5-year follow-up, with no signal of late-onset decline attributable to the therapy.
In everyday terms, parents reported that children who had previously responded only to very loud environmental sounds began turning to their names, following spoken instructions, and reacting to subtle cues such as footsteps or rustling paper. In older participants, restored access to high-frequency consonants improved lip-reading and made speech sound less distorted. While such qualitative reports are not substitutes for formal testing, they align with the objective audiometric data.
Bilateral delivery in children was explored in a separate single-arm study focused on pediatric patients with autosomal recessive deafness 9. That trial showed that treating both ears in a staged or simultaneous fashion is technically feasible and produced early functional gains in binocular-like hearing across the two ears. The bilateral approach matters because sound localization and speech comprehension in noisy environments depend on input from both cochleae, not just one, allowing the brain to compare timing and intensity differences between ears.
Regeneron’s parallel DB-OTO program used a dual-AAV strategy and advanced through the Phase 1/2 CHORD trial, which began with unilateral dosing at lower vector concentrations before escalating and expanding to bilateral administration. The FDA’s April 23, 2026 approval of OTARMENI drew on this body of evidence as well as natural-history data showing that untreated OTOF-related deafness does not spontaneously improve. Regulators accepted comparisons against these natural-history controls rather than insisting on a placebo group, reflecting the ethical difficulty of withholding a plausible restorative therapy from deaf children once early benefit had been documented.
Open questions on durability, access, and re-dosing
The 2.5-year follow-up is encouraging but still short relative to a human lifespan. Whether the AAV1-delivered gene will continue producing functional otoferlin at age 10, 20, or 40 remains unknown. AAV-based gene therapies in other tissues have shown multi-year expression, but the cochlea is a small, enclosed organ, and subtle inflammatory or degenerative changes could emerge only with longer observation. At present, systematic immunological monitoring beyond 52 weeks is limited, and no late safety signal has yet been identified.
Another unresolved question is how to manage re-dosing. Because AAV vectors can trigger neutralizing antibodies, a second infusion might be less effective or carry higher risk. A re-administration study that followed patients for 26 to 52 weeks after treating the opposite ear found that contralateral dosing was feasible when pre-existing antibody levels were low and remained stable, suggesting that children who initially receive unilateral treatment can later be offered therapy in the second ear without obvious immune-related complications. However, these data are still early, and the long-term consequences of repeated AAV exposure in the inner ear are not fully characterized.
Clinicians also lack detailed, patient-level audiometric and speech trajectories beyond aggregate summaries. Without that granularity, it is difficult to identify early markers that distinguish robust responders from partial responders or non-responders. Such markers could include the speed of ABR recovery, the shape of pure-tone improvement across frequencies, or early language milestones after therapy. As more participants reach multi-year follow-up, richer datasets will be essential for refining counselling and setting realistic expectations for families.
Access may prove as challenging as biology. Intracochlear gene therapy requires highly specialized surgical teams, paediatric anaesthesia, and centres capable of sophisticated audiological testing and long-term follow-up. Many regions with high rates of consanguinity-and therefore higher prevalence of recessive deafness-lack such infrastructure. Even in well-resourced health systems, the one-time cost of gene therapy is likely to be substantial, raising questions about insurance coverage, public reimbursement, and equitable allocation when demand exceeds capacity.
Newborn screening will be another bottleneck. OTARMENI targets a specific genetic subtype of deafness; its benefits depend on identifying OTOF mutations early, ideally within the first months of life. Yet most hearing screening programmes still rely on physiological tests that detect hearing loss but not its genetic cause. Scaling up rapid, affordable genetic panels for infants who fail initial hearing screens will be crucial if families are to make informed decisions before the most sensitive developmental windows close.
For now, the approval of OTARMENI marks a turning point: a form of congenital deafness once considered permanent can, in many cases, be converted into functional hearing with a single procedure. The next phase will determine whether this breakthrough becomes a narrowly available intervention for a few dozen children each year, or the foundation of a broader shift in how health systems diagnose, counsel, and treat inherited hearing loss. Long-term data on durability, careful attention to safety, and deliberate investment in access will decide which of those futures prevails.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
